Cancer Research

#AI #AI / data analytics / healthtech / informatics #Cancer research #Drug design #Drug development #Drug discovery

First AI-designed immuno-oncology drug enters clinical trials

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More

#Cancer Research #News

#Cancer research #DNA #Drug delivery #Drug development #Drug discovery

Blocking a protein may overcome cancer resistance to PARP inhibitors

Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Drug development #Genetics / genomes #Laboratory data #Research

‘Patchwork’ tumours prevalent across multiple cancer types

Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours,… Read More

#Cancer Research #News

#Cancer research #Covid-19 #Institute of Cancer Research #Research

Funding cuts could capsize cancer research in the UK

Cancer research in the UK is at risk through a combination of proposed government funding cuts for UK science and the impact of the pandemic on charity funding, warns a leading cancer research institute. The Institute of Cancer Research (ICR) is revealing reductions of as much as a fifth in… Read More

#Cancer Research #News

#Cancer research #Covid-19 #Immunology / Virology & Vaccines #Research

Cancer drug lessens toxicity of protein from virus that causes Covid-19

The University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2 and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In experiments in fruit flies and human cell lines, the team discovered the cell process that the virus… Read More

#Cancer Research #Covid-19 #News

#Cancer #Clinical trial #Life sciences #Novel therapeutics #Oncology

SignalChem collaborates with Merck on advanced non-small cell lung cancer

SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL,… Read More

#Cancer Research #News

#Antibody #Cancer #Cancer research #Immune cells #Research

Cancer immunotherapy may also treat autoimmune diseases

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as… Read More

#Cancer Research #News

#Biotechnology #Cancer research #Immunology / Virology & Vaccines #Immunotherapy #mRNA

Consortium awarded EU Commission TIGER Grant of €6.9 million

eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases, has announced the award of a TIGER grant of €6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of… Read More

#Cancer Research #News

#Cancer research #Drug development #Institute of Cancer Research #Oncology #Therapeutics

Resistance-busting ICR drug enters clinical trial

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More

#Cancer Research #Editor's Choice #News

#Biologics / Biotechnology #Biotherapeutics #Cancer immunotherapy #Drug discovery

Bicara Therapeutics launches biologics for cancer immunotherapy

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a… Read More

#Cancer Research #News

#Biomarkers #Cancer research #Events #Immuno-oncology

Immodulon presents on clinical biomarker strategies

Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021,… Read More

#Cancer Research #News

#Cancer research #Diagnostics #Drug development #In vitro

Avacta enters diagnostic licensing deal with Biokit

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under… Read More

#Cancer Research #News